preterm-birth
(4)
Mirvie
Mirvie is a South San Francisco biotech using cell-free RNA signatures and machine learning to predict pregnancy complications - preeclampsia, preterm birth, fetal growth restriction - months before symptoms appear. Its flagship product Encompass is a blood test built on a foundational study of nearly 11,000 pregnancies.
Amelia Degenkolb
Amelia Degenkolb is the CEO and co-founder of Novocuff, a Mountain View medical device company building the Cervical Control System, a device designed to stabilize the cervix, retain amniotic fluid and prolong pregnancies threatened by preterm premature rupture of membranes. A biomedical engineer who spent seven years as the first employee and lead engineer at Alydia Health, she helped bring the Jada System for postpartum hemorrhage to market before that company's $240M acquisition by Organon. In July 2024 she raised an oversubscribed $26M Series A to fund a U.S. pivotal trial aimed at reducing preterm births, the leading cause of infant mortality worldwide.
Novocuff, Inc.
Novocuff, Inc. is a clinical-stage maternal health medical device company based in Mountain View, California, building the Novocuff Cervical Control System (CCS) - a device designed to stabilize and close the cervix, retain amniotic fluid, and extend pregnancy in cases of preterm prelabor rupture of membranes (PPROM) and cervical shortening. Founded in 2021 by Amelia Degenkolb and Donald Lee, the company raised an oversubscribed $26M Series A in 2024 (about $28M total) to fund its U.S. multicenter pivotal RETAIN trial, for which it secured FDA IDE approval in September 2025.
Maneesh Jain
Maneesh Jain is the CEO and Co-founder of Mirvie, a South San Francisco-based biotech company pioneering RNA-based blood tests to predict pregnancy complications like preeclampsia and preterm birth months before symptoms occur. A serial entrepreneur with 20+ years in life sciences and more than $1.5B in combined exits across five prior startups - including Ion Torrent (acquired by Life Technologies) and Cirina (acquired by GRAIL) - Jain trained at the Stanford Genome Technology Center and holds a BS from Caltech and a Master's in Applied Physics from Stanford. Mirvie has raised over $90 million from investors including Khosla Ventures, GV, General Catalyst, and the Gates Foundation, and received FDA Breakthrough Device Designation for its preeclampsia risk test in 2022.